Quarry LP Has $288,000 Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Quarry LP grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11,263.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,500 shares of the company’s stock after purchasing an additional 2,478 shares during the quarter. Quarry LP’s holdings in Neurocrine Biosciences were worth $288,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in NBIX. 1832 Asset Management L.P. boosted its stake in shares of Neurocrine Biosciences by 1,370.7% during the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after purchasing an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Neurocrine Biosciences by 639.6% during the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after acquiring an additional 363,863 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after acquiring an additional 228,444 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Neurocrine Biosciences by 9.6% during the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after acquiring an additional 216,500 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Neurocrine Biosciences by 40.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock worth $97,828,000 after acquiring an additional 203,934 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $126.42 on Friday. The firm has a fifty day moving average price of $120.07 and a two-hundred day moving average price of $131.19. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The company has a market cap of $12.80 billion, a price-to-earnings ratio of 33.89 and a beta of 0.34.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. Raymond James restated an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. BMO Capital Markets lowered their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Barclays lowered their price objective on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.